Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva

Int J Cancer. 2012 Jun 15;130(12):2874-85. doi: 10.1002/ijc.26345. Epub 2011 Aug 30.

Abstract

Human papillomavirus (HPV) infections may result in benign hyperplasia, caused by low-risk HPV types, or (pre)malignant lesions caused by high-risk HPV types. The molecular basis of this difference in malignant potential is not completely understood. Here, we performed gene profiling of different HPV infected vulvar tissues (condylomata acuminata (n = 5), usual type vulvar intraepithelial neoplasia (uVIN) (n = 9)) and control samples (n = 14) using Affymetrix Human U133A plus 2 GeneChips. Data were analyzed using OmniViz®, Partek® and Ingenuity® Software. Results were validated by real-time RT-PCR and immunostaining. Although similarities were observed between gene expression profiles of low- and high-risk HPV infected tissues (e.g., absence of estrogen receptor in condylomata and uVIN), high-risk HPV infected tissues showed more proliferation and displayed more DNA damage than tissues infected with low-risk HPV. These observations were confirmed by differential regulation of cell cycle checkpoints and by increased expression of DNA damage-biomarkers p53 and γH2AX. Furthermore, FANCA, FANCD2, BRCA1 and RAD51, key players in the DNA damage response, were significantly upregulated (p < 0.05). In addition, we compared our results with publicly available gene expression profiles of various other HPV-induced cancers (vulva, cervix and head-and-neck). This showed p16(INK4a) was the most significant marker to detect a high-risk HPV infection, but no other markers could be found. In conclusion, this study provides insight into the molecular basis of low- and high-risk HPV infections and indicates two main pathways (cell cycle and DNA damage response) that are much stronger affected by high-risk HPV as compared to low-risk HPV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alphapapillomavirus*
  • BRCA1 Protein / biosynthesis
  • Biomarkers, Tumor
  • Cell Cycle Checkpoints*
  • Condylomata Acuminata / genetics
  • Condylomata Acuminata / metabolism
  • Condylomata Acuminata / pathology
  • Condylomata Acuminata / virology
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • DNA Damage*
  • DNA Repair*
  • DNA, Viral / analysis
  • DNA, Viral / genetics
  • Fanconi Anemia Complementation Group A Protein / biosynthesis
  • Fanconi Anemia Complementation Group D2 Protein / biosynthesis
  • Female
  • Gene Expression Profiling
  • Histones / biosynthesis
  • Humans
  • Papillomavirus Infections / genetics*
  • Papillomavirus Infections / metabolism
  • Papillomavirus Infections / pathology
  • Papillomavirus Infections / virology
  • Rad51 Recombinase / biosynthesis
  • Tumor Suppressor Protein p53 / biosynthesis
  • Vulva / pathology*
  • Vulva / virology
  • Vulvar Diseases / genetics*
  • Vulvar Diseases / pathology
  • Vulvar Diseases / virology

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA, Viral
  • FANCA protein, human
  • FANCD2 protein, human
  • Fanconi Anemia Complementation Group A Protein
  • Fanconi Anemia Complementation Group D2 Protein
  • H2AX protein, human
  • Histones
  • Tumor Suppressor Protein p53
  • RAD51 protein, human
  • Rad51 Recombinase

Associated data

  • GEO/GSE5563